Dual-Energy CT Muscle Fat Fraction as a Prognostic Biomarker in ICU Patients

Overview

This study demonstrates that dual-energy CT (DECT) quantification of muscle fat fraction (FF) is a reliable and unbiased imaging biomarker for assessing muscle quality in critically ill ICU patients. DECT FF correlates with muscle changes during immobilization and shows potential predictive value for morbidity and survival, outperforming conventional CT parameters.

Background

Sarcopenia, characterized by loss of muscle mass and quality, is prevalent in critically ill patients and leads to adverse outcomes including prolonged ICU stay and increased mortality. Muscle quality, often compromised by myosteatosis (fat infiltration), is a key determinant of muscle function but challenging to assess in ICU settings. Conventional methods like CT muscle radiodensity attenuation (MRA) are limited by contrast agent effects. DECT offers a novel approach to directly quantify muscle fat content independent of contrast, potentially improving muscle quality assessment and prognostication in this vulnerable population.

Data Highlights

Patients included were intubated ICU patients undergoing two contrast-enhanced abdominal DECT scans at least 10 days apart. DECT scans were performed with dual-source CT at 100 kV and 150 kV with tin filter, with postprocessing generating virtual noncontrast images and fat maps. Muscle fat fraction was quantified in posterior paraspinal muscles at the third lumbar vertebra level. The study compared DECT FF with skeletal muscle index (SMI) and muscle radiodensity attenuation (MRA) to evaluate muscle changes and predictive value for clinical outcomes.

Key Findings

• DECT FF provides direct, contrast-agent independent quantification of muscle fat content, correlating well with MRI fat quantification methods.
• In immobilized ICU patients, DECT FF detected significant increases in muscle fat fraction over time, indicating worsening muscle quality.
• Conventional CT parameters such as SMI and MRA showed limitations due to contrast effects and edema, whereas DECT FF remained reliable.
• Higher muscle fat fraction measured by DECT FF was associated with poorer clinical outcomes, including increased morbidity and reduced survival.
• DECT FF may serve as a novel imaging biomarker for early detection of sarcopenia and myosteatosis in critically ill patients.

Clinical Implications

DECT muscle fat fraction quantification offers a practical and accurate tool for monitoring muscle quality in ICU patients, overcoming limitations of conventional CT and clinical muscle strength assessments. Early identification of muscle deterioration via DECT FF can guide timely interventions such as nutritional support and physical therapy to mitigate sarcopenia-related complications. Incorporating DECT FF into routine imaging protocols may improve prognostication and personalized management in critically ill populations.

Conclusion

DECT-based muscle fat fraction quantification is a promising, noninvasive imaging biomarker for assessing muscle quality and predicting outcomes in critically ill patients. Its integration into clinical practice could enhance sarcopenia detection and improve patient care in the ICU setting.

References

1. Molwitz et al 2023 -- Validation of DECT Muscle Fat Quantification
2. STROBE Guidelines 2021 -- Reporting Observational Studies